Thioguanine used in maintenance therapy of chronic myeloid leukaemia causes non-cirrhotic portal hypertension. Results from MRC CML. II. Trial comparing busulphan with busulphan and thioguanine.

Thioguanine used in maintenance therapy of chronic myeloid leukaemia causes non-cirrhotic portal hypertension. Results from MRC CML. II. Trial comparing busulphan with busulphan and thioguanine.

Portal hypertension with varices developed in 18/675 patients with chronic myeloid leukaemia (CML) in a randomized trial comparing busulphan with busulphan and thioguanine. All 18 had received the drug combination and none busulphan alone (P less than 0.0001). Ascites was also seen significantly mor...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Shepherd, P, Fooks, J, Gray, R, Allan, N
Format:	Journal article
Język:	English
Wydane:	1991

Podobne zapisy

Oesophageal varices associated with busulphan-thioguanine combination therapy for chronic myeloid leukaemia.
od: Key, N, i wsp.
Wydane: (1987)

Severe cytopenias associated with the sequential use of busulphan and interferon-alpha in chronic myeloid leukaemia.
od: Shepherd, P, i wsp.
Wydane: (1994)

Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data meta-analysis of three randomized trials
od: Hehlmann, R, i wsp.
Wydane: (2000)

Progress with interferon in CML--results of the MRC UK CML III study.
od: Shepherd, P, i wsp.
Wydane: (1996)

Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial.
od: Vora, A, i wsp.
Wydane: (2006)

The clinical pharmacology of thioguanine vs. mercaptopurine in ALL97, a randomized trial for the treatment of childhood lymphoblastic leukaemia
od: Lennard, L, i wsp.
Wydane: (2008)

Thioguanine versus mercaptopurine in ALL97: thiopurine metabolism and treatment outcome
od: Lennard, L, i wsp.
Wydane: (2008)

Thioguanine compared with mercaptopurine in childhood lymphoblastic leukaemia: Results of the United Kingdom medical research council randomised trial ALL97.
od: Lennard, L, i wsp.
Wydane: (2005)

MRC ALL97/99 - A randomized comparison of dexamethasone versus prednisolone and thioguanine versus mercaptopurine in the treatment of childhood acute lymphoblastic leukemia.
od: Mitchell, C, i wsp.
Wydane: (2002)

Thioguanine-related veno-occlusive disease (VOD) of the liver in children with acute lymphoblastic leukaemia (ALL): Report from United Kingdom Medical Research Council (UK MRC) trial ALL97.
od: Vora, A, i wsp.
Wydane: (2002)

6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance.
od: Issaeva, N, i wsp.
Wydane: (2010)

INTERFERON-ALPHA(IFN-ALPHA) PROLONGS SURVIVAL FOR PATIENTS WITH CML IN CHRONIC PHASE - PRELIMINARY-RESULTS OF THE UK MRC RANDOMIZED MULTICENTER TRIAL
od: Allan, N, i wsp.
Wydane: (1994)

Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults.
od: Catovsky, D, i wsp.
Wydane: (1989)

Pharmacological and toxicological effects of 6-hydroxy-2-mercaptopurine and 6-thioguanine in in vitro and in vivo models of arthritis
od: Nordin, Nurul Syuhada
Wydane: (2021)

The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia.
od: Lennard, L, i wsp.
Wydane: (2006)

An imaging-based artificial intelligence model for non-invasive grading of hepatic venous pressure gradient in cirrhotic portal hypertension
od: Yu, Q, i wsp.
Wydane: (2022)

Identifying regulators of chronic myeloid leukaemic (CML) stem cell quiescence and discovering effective novel therapies for CML relapse
od: Xu, Z
Wydane: (2022)

Interferon-alpha therapy in chronic myeloid leukaemia is probably better than hydroxyurea alone.
od: Allan, N, i wsp.
Wydane: (1995)

Autografting for patients with CML in chronic phase: an update. Hammersmith BMT Team LRF Centre for Adult Leukaemia.
od: Hoyle, C, i wsp.
Wydane: (1994)

Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party.
od: Webb, D, i wsp.
Wydane: (1999)

Harnessing cooperative multivalency in thioguanine for surface-enhanced raman scattering (SERS)-based differentiation of polyfunctional analytes differing by a single functional group
od: Nguyen, Lam Bang Thanh, i wsp.
Wydane: (2024)

Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party.
od: Chessells, J, i wsp.
Wydane: (2002)

Clonal structures of leukaemia stem cell populations in myeloid blast phase chronic myeloid leukaemia
od: Karamitros, D, i wsp.
Wydane: (2016)

Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study
od: Milojkovic, D, i wsp.
Wydane: (2020)

BONE-MARROW TRANSPLANTATION (BMT) FOR CHRONIC MYELOID-LEUKEMIA (CML) USING MATCHED UNRELATED DONORS
od: Mackinnon, S, i wsp.
Wydane: (1988)

BONE-MARROW TRANSPLANTATION (BMT) FOR CHRONIC MYELOID-LEUKEMIA (CML) USING MATCHED UNRELATED DONORS
od: Mackinnon, S, i wsp.
Wydane: (1988)

Treatment of high risk leukaemia - Results of MRC childhood acute lymphoblastic leukaemia study MRC HR-1.
od: Kinsey, S, i wsp.
Wydane: (2002)

Low expression of the putative tumour suppressor gene gravin in chronic myeloid leukaemia, myelodysplastic syndromes and acute myeloid leukaemia.
od: Boultwood, J, i wsp.
Wydane: (2004)

Imatinab mesylate treatment in Chronic Myeloid Leukemia (CML)- understanding the fundamental pharmacokinetic and pharmacogenetic mechanisms for variation in response
od: Ankathil, Ravindran
Wydane: (2016)

Analysis of GATA-1 mutations in chronic myeloid leukaemia.
od: Halsey, C, i wsp.
Wydane: (2006)

GATA1 mutational analysis in chronic myeloid leukaemia.
od: Halsey, C, i wsp.
Wydane: (2007)

A randomised comparison of low or high dose IFN-alpha in newly diagnosed CML patients shows no difference in major cytogenetic response rate or survival between the two groups - Results of MRC CML V and HOVON 20 trials.
od: Shepherd, P, i wsp.
Wydane: (2001)

Continuing (maintenance) therapy in lymphoblastic leukaemia: lessons from MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia.
od: Chessells, J, i wsp.
Wydane: (1997)

UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia.
od: Allan, N, i wsp.
Wydane: (1995)

Nitric oxide (NO) secretion inhibition and cytotoxicity effects of LPS-induced RAW 264.7 macrophage cells and PMA-induced HIG-82 cells by 6-hydroxy-2-mercaptopurine and 6-thioguanine
od: Nordin, Nurul Syuhada, i wsp.
Wydane: (2014)

Harnessing the graft-versus-leukaemia effect in acute myeloid leukaemia
od: Sweeney, C
Wydane: (2021)

Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party.
od: Secker-Walker, L, i wsp.
Wydane: (1997)

Enhanced thrombin generation in cirrhotics with coagulopathy and variceal bleeding
od: Harrison, P, i wsp.
Wydane: (2011)

No support for linkage of chromosome 17(q21-24) to Essential Hypertension in the MRC British Genetics of Hypertension (MRC BRIGHT) Study.
od: Knight, J, i wsp.
Wydane: (2001)

Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia.
od: Foroni, L, i wsp.
Wydane: (2011)